Dofu Cat makes four litter varieties: cereal, tofu, multi-cat, and coffee bean. The multi-cat variety is made with bean fiber ...

Cassava faces a cash burn of $80-$90 million in the second half of 2024, which will significantly reduce its current cash runway. Due to data integrity issues and unproven efficacy, I maintain a ...

Arrowroot (Maranta arundinacea) is a tropical tuber native to Indonesia ... Arrowroot is a starchy root vegetable similar to yam, cassava, sweet potato, and taro. Like many starches, it’s ...

THE African Agricultural Technology Foundation (AATF), has kickstarted the training of no fewer than 6,000 cassava farmers ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...

The research behind Cassava Sciences’ Alzheimer’s drug candidate, simufilam, and the idea of targeting a brain protein called filamin, is based on a series of papers from a group at CUNY and ...

WASHINGTON, Sept 26 (Reuters) - Shares of Cassava Sciences (SAVA.O), opens new tab fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the ...

Alzheimer’s drug developer Cassava Sciences agreed Thursday to pay $40 million to settle regulatory claims that it misled investors about the results of a clinical trial that showed promise for ...

Cassava Sciences faced a $40 million penalty to focus on Simufilam's development following SEC charges over misleading trial data. Cassava Sciences completed ReTHINK Phase 3 trial with 804 ...

Cassava, without admitting or denying the SEC’s allegations, agreed to pay a monetary penalty of $40 million. The Company cooperated fully with the SEC’s investigation and has implemented ...

Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The firm anticipates top-line results from the ReTHINK Phase 3 trial before ...

WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former ...